NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
KHEDEZLA (desvenlafaxine) by Hikma is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. First approved in 2013.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KHEDEZLA (desvenlafaxine) is an oral extended-release SNRI approved in 2013 for major depressive disorder. It works by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, with high selectivity and no significant affinity for muscarinic, histaminergic, or adrenergic receptors. The drug demonstrates linear pharmacokinetics, achieves steady-state within 4–5 days, and has minimal drug–drug interactions due to limited CYP metabolism involvement.
Peak
Product is in peak lifecycle phase under Hikma sponsorship with moderate competitive pressure (30%), indicating sustained commercial activity and ongoing market defense efforts.
Mechanism of Action
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). 12.2…
Worked on KHEDEZLA at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.